Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly ...

To schedule a 1x1 meeting with the Company, please contact your Jefferies representative at healthcareconference@jefferies.com. The live and archived webcast will be ...

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to ...

Bright Minds Biosciences (NASDAQ: DRUG), a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading ...

Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted. Less than ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the capital of the ...

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, succeeded in a mid-stage trial for adults with Absence Seizures and ...

Bright Minds Biosciences announced a non-brokered private placement with expected gross proceeds of $35 million. The company's stock is currently trading with a session volume of about 10.6 million.

Bright Minds Biosciences, Inc. ('Bright Minds,” 'BMB” or the 'Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant ...